MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.
Jean-Louis Pujol
Consultant or Advisory Role - Abscience; Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; Chugai Pharma; Genentech; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche; Vifor France
Johan F. Vansteenkiste
Consultant or Advisory Role - GlaxoSmithKline
Tommaso Martino De Pas
Honoraria - GlaxoSmithKline
Djordje Atanackovic
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Merck; Roche
Michiel Thomeer
No relevant relationships to disclose
Jean-Yves Douillard
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Gianpiero Fasola
Consultant or Advisory Role - Amgen; Lilly; Roche
Stock Ownership - Novartis
Honoraria - Merck Serono
Vanessa Potter
No relevant relationships to disclose
Paul Taylor
Other Remuneration - GlaxoSmithKline
Lionel Bosquee
No relevant relationships to disclose
Muriel Debois
Employment or Leadership Position - GlaxoSmithKline
Pedro de Sousa Alves
Employment or Leadership Position - GlaxoSmithKline
Jamila Louahed
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Frederic Lehmann
Employment or Leadership Position - GlaxoSmithKline
Vincent G. Brichard
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline